NUTRIREA-3: where to next?
- PMID: 37028438
- DOI: 10.1016/S2213-2600(23)00128-5
NUTRIREA-3: where to next?
Conflict of interest statement
EJR reports grants and personal fees for speaking from Baxter Healthcare (USA); grants and personal fees for speaking from Baxter Healthcare (Australia), Nutricia Australia, and Fresenius Kabi; and personal fees for speaking from Nestlé (Australia), all outside of the submitted work. TWR reports consulting fees from Nestlé and Baxter and serves as Director of Medical Affairs for Cumberland Pharmaceuticals.
Comment on
-
Low versus standard calorie and protein feeding in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group trial (NUTRIREA-3).Lancet Respir Med. 2023 Jul;11(7):602-612. doi: 10.1016/S2213-2600(23)00092-9. Epub 2023 Mar 20. Lancet Respir Med. 2023. PMID: 36958363 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical